1429.3000 -7.50 (-0.52%)
NSE Dec 02, 2025 11:55 AM
Volume: 44,759
 

1429.30
-0.52%
Deven Choksey
Tatva Chintan is transitioning into a stronger growth phase primarily driven by SDA recovery, clearer electrolyte-salt commercialization, scalable agro/pharma pipelines, and a structurally high-entry-barrier semiconductor opportunity.
Tatva Chintan Pharma Chem Ltd. is trading above its 200 day SMA of 981.9
More from Tatva Chintan Pharma Chem Ltd.
Recommended